Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Zika virus-like particle (VLP) based vaccine

Open access
Boigard, Hélène, Alimova, Alexandra, Martin, George R., Katz, Al, Gottlieb, Paul, Galarza, Jose M. · 2017 · PLOS Neglected Tropical Diseases

Abstract

The newly emerged mosquito-borne Zika virus poses a major public challenge due to its ability to cause significant birth defects and neurological disorders.The impact of sexual transmission is unclear but raises further concerns about virus dissemination.No specific treatment or vaccine is currently available, thus the development of a safe and effective vaccine is paramount.Here we describe a novel strategy to assemble Zika virus-like particles (VLPs) by co-expressing the structural (CprME) and non-structural (NS2B/NS3) proteins, and demonstrate their effectiveness as vaccines.VLPs are produced in a suspension culture of mammalian cells and self-assembled into particles closely resembling Zika viruses as shown by electron microscopy studies.We tested various VLP vaccines and compared them to analogous compositions of an inactivated Zika virus (In-ZIKV) used as a reference.VLP immunizations elicited high titers of antibodies, as did the In-ZIKV controls.However, in mice the VLP vaccine stimulated significantly higher virus neutralizing antibody titers than comparable formulations of the In-ZIKV vaccine.The serum neutralizing activity elicited by the VLP vaccine was enhanced using a higher VLP dose and with the addition of an adjuvant, reaching neutralizing titers greater than those detected in the serum of a patient who recovered from a Zika infection in Brazil in 2015.Discrepancies in neutralization levels between the VLP vaccine and the In-ZIKV suggest that chemical inactivation has deleterious effects on neutralizing epitopes within the E protein.This along with the inability of a VLP vaccine to cause infection makes it a preferable candidate for vaccine development. Author summaryZika is an emerging mosquito-borne infection for which vaccines or specific treatments are not available to combat and control its rapid dissemination and deleterious effects.This work describes a novel strategy for the development of a virus-like particle (VLP) based Zika vaccine and shows its effectiveness when tested in a murine model.VLPs are non-infections mimics of the Zika virus, thus chemical inactivation is not required.A VLP vaccine is able to maintain native epitopes structures and to perform better than an inactivated Zika virus control.Our results show feasibility for the rapid development of a safe and potentially highly effective VLP based Zika vaccine for humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pntd.0005608

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 159

Metadata

Authors
Boigard, H., Alimova, A., Martin, G. R., Katz, A., Gottlieb, P., & Galarza, J. M.
Venue
PLOS Neglected Tropical Diseases
Published
2017-05-08
Volume
11
Issue
5
Pages
e0005608
ISSN
  • 1935-2727 (ISSN-L)
  • 1935-2735
OpenAlex
W2613515801
Cited by
159
References
1
FWCI
20.50
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zika virus-like particle (VLP) based vaccine. https://app.cochat.ai/papers/10.1371/journal.pntd.0005608
The paper
Boigard, H., Alimova, A., Martin, G. R., Katz, A., Gottlieb, P., & Galarza, J. M. (2017). Zika virus-like particle (VLP) based vaccine. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0005608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.